We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Cardiology

Physical Activity Trajectories Before and After Cardiovascular Disease: Insights from the CARDIA Study

MedXY Editorial Team•Sep 30, 2025•Cardiology
cardiovascular diseasedisparitiesPhysical Activity

Highlight

  • Moderate to vigorous physical activity (MVPA) declines steadily from young adulthood into midlife, plateauing thereafter, as shown by CARDIA data.
  • Individuals who experienced cardiovascular disease (CVD) events had a sharper pre-event decline in MVPA, especially in the 12 years leading up to their event, with a further steep drop in the last 2 years before CVD onset.
  • Post-CVD, MVPA levels remain persistently lower compared to matched controls, with Black women facing the steepest declines and highest risk for sustained low activity.
  • Findings underscore the urgent need for tailored strategies to promote lifelong activity and reduce disparities in CVD outcomes.

Background

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Impact of Age at Type 1 Diabetes Onset on Mortality and Organ Complications: Insights from a Nationwide Swedish CohortYounger age at type 1 diabetes diagnosis significantly increases risks of mortality, cardiovascular, and kidney complications; each additional year delay in onset reduces these risks. This review synthesizes nationwide cohort findings and cSep 23, 2026Efficacy and Safety of Semaglutide According to Frailty Status: Insights from the SELECT Randomized Clinical Trial Post Hoc AnalysisSemaglutide demonstrates consistent cardiovascular benefits and safety across frailty levels in overweight adults with cardiovascular disease, enhancing quality of life and frailty status without increased adverse events.Sep 21, 2026Differential Physical Activity Responses to Diabetes Risk Reduction Interventions According to Prediabetes Phenotype: Insights from Pooled Randomized Controlled TrialsThe effectiveness of lifestyle interventions promoting physical activity for diabetes risk reduction varies by prediabetes phenotype, with individuals having impaired fasting glucose showing the least response. Tailored approaches may enhanSep 17, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
General Surgery
Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Subclinical Liver Disease as a Silent Driver of Cardiovascular Risk: Insights from a Large-Scale Prospective StudySubclinical liver disease, marked by steatosis, fibrosis, and functional impairment, independently and synergistically increases cardiovascular disease risk. Incorporating non-invasive liver biomarkers could enhance CVD risk prediction andSep 15, 2026
Unveiling the Cardiovascular Toll of Long-Term Wildfire Smoke PM2.5 Exposure in Older AmericansLong-term cumulative exposure to wildfire smoke PM2.5 significantly increases cardiovascular hospitalizations among U.S. older adults, with notable risks in ischemic heart disease and arrhythmias, highlighting the need for targeted public hSep 15, 2026
Designing Cardiovascular Outcomes Trials in Clonal Hematopoiesis: A Precision Medicine ImperativeClonal hematopoiesis of indeterminate potential (CHIP) poses a novel cardiovascular risk. This article explores challenges and strategies for designing cardiovascular outcomes trials tailored to CHIP’s genetic heterogeneity and clinical comSep 15, 2026